Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Operating Expenses (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Operating Expenses readings, the most recent being $39.6 million for Q1 2026.

  • Quarterly Operating Expenses rose 21.09% to $39.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $149.9 million through Mar 2026, up 2.24% year-over-year, with the annual reading at $143.0 million for FY2025, 0.08% changed from the prior year.
  • Operating Expenses hit $39.6 million in Q1 2026 for Oric Pharmaceuticals, up from $34.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $39.6 million in Q1 2026 and bottomed at $20.7 million in Q2 2022.
  • Average Operating Expenses over 5 years is $31.1 million, with a median of $31.4 million recorded in 2023.
  • The largest annual shift saw Operating Expenses skyrocketed 44.11% in 2024 before it decreased 12.68% in 2025.
  • Oric Pharmaceuticals' Operating Expenses stood at $22.1 million in 2022, then surged by 42.09% to $31.4 million in 2023, then grew by 25.91% to $39.6 million in 2024, then fell by 12.68% to $34.6 million in 2025, then grew by 14.67% to $39.6 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Operating Expenses are $39.6 million (Q1 2026), $34.6 million (Q4 2025), and $36.7 million (Q3 2025).